HHS said to be eyeing two new FDA deputy commissioners for technology and drugs
Seeking Alpha News (Tue, 25-Aug 1:53 PM ET)
Certara Maintains 2026 Growth Targets with Strong Software Momentum and Strategic Streamlining
Market Chameleon (Tue, 4-Aug 3:38 AM ET)
Certara Reports Second Quarter 2026 Financial Results
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
PRNewswire (Thu, 23-Jul 10:01 AM ET)
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
Globe Newswire (Wed, 15-Jul 4:15 PM ET)
Certara's AI Partnership with NVIDIA Signals Step-Change in Drug Development Workflow
Market Chameleon (Tue, 7-Jul 4:55 AM ET)
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
Globe Newswire (Tue, 7-Jul 8:00 AM ET)
PRNewswire (Mon, 6-Jul 8:55 AM ET)
PRNewswire (Mon, 6-Jul 8:45 AM ET)
Globe Newswire (Fri, 19-Jun 2:11 PM ET)
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Certara trades on the NASDAQ stock market under the symbol CERT.
As of August 27, 2026, CERT stock price climbed to $8.40 with 704,881 million shares trading.
CERT has a beta of 1.94, meaning it tends to be more sensitive to market movements. CERT has a correlation of 0.12 to the broad based SPY ETF.
CERT has a market cap of $1.28 billion. This is considered a Small Cap stock.
Last quarter Certara reported $93 million in Revenue and $.08 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.01.
In the last 3 years, CERT traded as high as $19.87 and as low as $4.45.
The top ETF exchange traded funds that CERT belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
CERT has underperformed the market in the last year with a return of -22.7%, while SPY returned +20.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CERT shares. However, CERT has outperformed the market in the last 3 month and 2 week periods, returning +61.2% and +4.9%, while SPY returned +2.9% and -0.2%, respectively. This indicates CERT has been having a stronger performance recently.
CERT support price is $7.99 and resistance is $8.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CERT shares will trade within this expected range on the day.